Progressive – Talk Bio

Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment

2 months ago talkbio0Tagged Boehringer, FIBRONEER-ILD, Force, Idiopathic Pulmonary Fibrosis, Ingelheim, nerandomilast, Phase 3 Clinical Trials, Progressive, Pulmonary Fibrosis, Respiratory physiology, Vital capacity

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity

Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval

2 months ago talkbio0Tagged Approved, Boehringer, FIBRONEER-ILD, fibrosing, Improvement, Ingelheim, Inhibitor, nerandomilast, PF-ILDs, Phase 3 Clinical Trials, phosphodiesterase 4B, Progressive, Respiratory physiology, United States Food and Drug Administration

Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor

FDA Approves Ocrevus Zunovo: A Breakthrough Subcutaneous Injection for Multiple Sclerosis

7 months ago talkbio0Tagged Approved, drug delivery technology, ENHANZE, Halozyme, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Ocrevus Zunovo, PPMS, Progressive, Relapsing Multiple Sclerosis, RMS, Subcutaneous Injections, United States Food and Drug Administration

Ocrevus Zunovo, FDA Approval, Subcutaneous Injection, Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS), Halozyme Therapeutics, ENHANZE drug delivery technology.